Initial clinical studies of afamelanotide showed the drug could repigment skin. This patient received four afamelanotide implants and NB-UVB light therapy over six months, largely repigmenting lesions on their eyelids. Images taken at days 0 and 171 of CUV102 study, courtesy of the study investigator.
Initial clinical studies of afamelanotide showed the drug could repigment skin. This patient received four afamelanotide implants and NB-UVB light therapy over six months, largely repigmenting lesions on their eyelids. Images taken at days 0 and 171 of CUV102 study, courtesy of the study investigator.